3 Defendants Oppose MDL For Onglyza Diabetes Drug Federal Lawsuits

Mealey's (November 10, 2017, 1:27 PM EST) -- WASHINGTON, D.C. — The three defendants in a proposed Onglyza/Kombiglyze multidistrict litigation on Nov. 2 told a federal judicial panel that it should deny centralization because there are fewer than 40 cases after two years of litigation and one plaintiff law firm represents most plaintiffs (In Re:  Onglyza and Kombiglyze XR Products Liability Litigation, MDL Docket No. 2809, JPMDL)....

Attached Documents

Related Sections